A clinical trial assessing CG0416
Latest Information Update: 30 May 2025
At a glance
- Drugs CG 0416 (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity
- Focus Adverse reactions
Most Recent Events
- 30 May 2025 New trial record
Latest Information Update: 30 May 2025